ASCO 2016: Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib in CLL

We are 8 weeks out from the 2016 annual meeting of the American Society of Hematology and realize that we have quite a few interviews from the ASCO and EHA meetings that have not yet been posted, so we’ll be posting twice a week until they are all out the door on the CLL Society's website.

If you have not yet participated in our Reader Poll to give us feedback about how we’re doing and what topics you would like to see covered in the future, please take 2 minutes and do so if you have time. You can access it here. q32016ask.questionpro.com/

We just posted an interview from ASCO 2016 with Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib, a promising second-generation BTK inhibitor. You can access my article, the abstract and our interview here. cllsociety.org/2016/10/asco...

NEW Patient & Caregiver Support Meetings

Tuesday, October 18th at 6:30 PM at the Levine Cancer Institute in Charlotte, NC – the first meeting of a new CLL Patient & Caregiver Support and Education Group. Patients and family caregivers are welcome. Find out more about dates and registration here. cllsociety.org/docs/CLL%20P...

Tuesday, November 1st at 6:30 PM at the Moffitt McKinley Outpatient Center in Tampa, FL – the first meeting of a new CLL Patient & Caregiver Support and Education Group. Patients and family caregivers are welcome. You can find more information here! cllsociety.org/docs/Tampa%2...

If you’re aware of other CLL Patient Support Group meetings, let us know and we’ll post them.

Thanks. Stay strong

Brian

cllsociety.org

Skip

Featured Content

HealthUnlocked User Stories

How did you improve your fitness, general well-being or cope with your illness?

Share your story

Featured by HealthUnlocked

6 Replies

oldestnewest
  • This does look very hopeful, thanks for posting. How is Acalabrutinib pronounced and where has it come from?

  • Used to be ACP-196... Acerta Pharma... now owned by AstraZeneca... it will be starting the FDA approval process this winter...

    pronounced acala-brut-i-nib

    It is a second generation drug that targets the same pathway as ibrutinib, but with fewer side effects it is believed.

    ~chris

  • Hi Chris

    Wonder if you have heard that Acalabrutinib had been approved by FDA for front line CLL treatment recently?

    I'm hoping my Hb don't drop any further from 9.6; let me have some time to wait for Acalabrutinib. Cause I have family history of Afib & RT possibility sounds scary.

    Seok

  • Seok

    Acalabrutinib should be FDA approved for second line, hopefully late next spring.

    It will be some time before firstline approval, typically a year or two more...

    RT can happen at any time... although more is seen after treatment than before... any treatment, regrettably.

    Waiting for approvals may not be in your best interest, you need to talk to your CLL specialist hemetologist about your treatment options...

    ~chris

  • Thanks Chris, Dr said trials on acalabrutinib are off the table for me at the moment. Ibrutinib was my only choice. Guessed it makes life easier for me not having to decide & look forward for brighter days with Ibrutinib.

  • Very interesting short interview. Looking forward to seeing more information as it becomes available. rob

You may also like...